Lyka Labs Ltd
LYKALABSLyka Labs Ltd
LYKALABS
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 175.41 | 7.92 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Lyka Labs Limited is a pharmaceutical products and services provider. The Company is primarily engaged in formulation and manufacturing lyophilized products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 146.54 | 112.32 | 65.39 | 72.87 | 66.33 | 87.81 | 196.17 | 96.72 | 112.64 | 133.04 | ||||||||||
Raw Materials | 67.90 | 55.78 | 27.58 | 35.80 | 36.46 | 34.91 | 53.38 | 38.76 | 45.64 | 114.05 | ||||||||||
| Power & Fuel Cost | 1.39 | 1.90 | 1.86 | 2.28 | 2.56 | 2.94 | 3.92 | 3.60 | 3.93 | |||||||||||
| Employee Cost | 14.71 | 17.24 | 16.98 | 14.69 | 13.86 | 14.57 | 18.06 | 18.61 | 26.77 | |||||||||||
| Selling & Administrative Expenses | 16.47 | 6.33 | 8.76 | 11.30 | 9.00 | 7.57 | 13.92 | 12.71 | 16.05 | |||||||||||
| Operating & Other expenses | 17.65 | 10.20 | 9.39 | 9.75 | 38.24 | 7.71 | 10.17 | 10.19 | 3.50 | |||||||||||
EBITDA | 28.42 | 20.87 | 0.82 | -0.95 | -33.79 | 20.11 | 96.72 | 12.85 | 16.75 | 18.99 | ||||||||||
| Depreciation/Amortization | 9.32 | 10.25 | 11.28 | 7.31 | 8.01 | 8.32 | 17.35 | 14.15 | 12.80 | 9.26 | ||||||||||
| PBIT | 19.10 | 10.62 | -10.46 | -8.26 | -41.80 | 11.79 | 79.37 | -1.30 | 3.95 | 9.73 | ||||||||||
| Interest & Other Items | 15.19 | 18.72 | 9.58 | 7.17 | 20.07 | 25.94 | 20.13 | 11.87 | 4.89 | 3.54 | ||||||||||
| PBT | 3.91 | -8.10 | -20.04 | -15.43 | -61.87 | -14.15 | 59.24 | -13.17 | -0.94 | 6.19 | ||||||||||
| Taxes & Other Items | 0.21 | -2.57 | -2.77 | -9.87 | -1.33 | -2.60 | 20.24 | 0.04 | 1.56 | 3.06 | ||||||||||
| Net Income | 3.70 | -5.53 | -17.27 | -5.56 | -60.54 | -11.55 | 39.00 | -13.21 | -2.50 | 3.13 | ||||||||||
| EPS | 1.70 | -2.51 | -6.88 | -1.98 | -21.31 | -4.03 | 13.59 | -4.45 | -0.78 | 0.95 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Lyka Labs Ltd | -219.61 | 7.92 | — |
| Sun Pharmaceutical Industries Ltd | 45.12 | 6.44 | 0.75% |
| Cipla Ltd | 28.85 | 4.44 | 0.88% |
| Torrent Pharmaceuticals Ltd | 69.10 | 16.69 | 0.83% |
Price Comparison
Compare LYKALABS with any stock or ETFShareholdings
Promoter Holdings Trend
Increased Total Promoter Holding
In last 6 months, promoter holding in the company has increased by 3.29%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.22%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Apr 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
LYKALABS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Lyka Labs reported to Rs 2.10 crore in the quarter ended September 2024 as against net loss of Rs 0.49 crore during the previous quarter ended September 2023. Sales rose 47.05% to Rs 41.16 crore in the quarter ended September 2024 as against Rs 27.99 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales41.1627.99 47 OPM %12.0314.90 - PBDT4.443.23 37 PBT2.67-0.36 LP NP2.10-0.49 LP Powered by Capital Market - Live
Lyka Labs will hold a meeting of the Board of Directors of the Company on 12 November 2024.Powered by Capital Market - Live
Lyka Labs will hold a meeting of the Board of Directors of the Company on 11 October 2024Powered by Capital Market - Live
Net profit of Lyka Labs reported to Rs 1.44 crore in the quarter ended June 2024 as against net loss of Rs 1.85 crore during the previous quarter ended June 2023. Sales rose 31.60% to Rs 30.11 crore in the quarter ended June 2024 as against Rs 22.88 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales30.1122.88 32 OPM %12.3211.54 - PBDT3.621.67 117 PBT1.86-1.80 LP NP1.44-1.85 LP Powered by Capital Market - Live
Lyka Labs will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
Lyka Labs announced that the Annual General Meeting (AGM) of the company will be held on 9 August 2024.Powered by Capital Market - Live
Lyka Labs Consolidated September 2023 Net Sales at Rs 27.99 crore, up 9.64% Y-o-Y
Lyka Labs Standalone June 2023 Net Sales at Rs 21.24 crore, down 2.93% Y-o-Y
Stocks that will see action on March 22, 2023
Kohinoor Foods Ltd leads losers in ‘B’ group
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.1%, vs industry avg of 9.03%
Constant Market Share
Over the last 5 years, market share stayed at 0.03%